University Hospital of Nantes Presents 18-Year Experience with SynCardia’s Total Artificial Heart

French Hospital Achieves 5-Year Post-Transplant Survival of 78% for Patients Bridged to Transplant with Total Artificial Heart

TUCSON, Ariz.--(BUSINESS WIRE)-- On Oct. 17, Dr. Jean Christian Roussel from the Thorax Institute at University Hospital of Nantes presented the center’s 18-year experience with the SynCardia temporary Total Artificial Heart at the Acute Cardiac Care 2010 medical meeting in Copenhagen, Denmark. The aim of the single center, retrospective study was to assess both the comorbidity and survival of patients awaiting heart transplants while supported by SynCardia’s Total Artificial Heart.

The study’s authors concluded that the SynCardia Total Artificial Heart “is an excellent bridge-to-transplant device for patients with biventricular failure. Our study demonstrates excellent safety, reliability and efficiency. Exceptional outcome after transplantation underlines its capacity to aid in end-organ recovery.”

The study included 46 patients who received the Total Artificial Heart from 1990 to April 2008. Seventy-two percent (33) of these Total Artificial Heart patients were bridged to transplant. At one year post-transplant, 88% of these patients were alive, and at five years, 78%. The overall survival for all patients who received the Total Artificial Heart at five years was >55%.

Duration of support was 1 to 502 days with a mean of 113± 106 days. Of the 13 patients who died during support, the leading cause of death was multi-organ failure (6). No device malfunctions led to patient death. Adverse events included stroke in 4 patients and infections in 37 patients.

The mean age at time of implantation was 46 (±9.8) and 96% (42) of patients were men. Idiopathic or dilated cardiomyopathy was the pre-implant diagnosis in 43.5% (20) of patients and ischemic cardiomyopathy in 43.5% (20) of patients.

About SynCardia Systems, Inc.

SynCardia Systems, Inc. is the Tucson-based manufacturer of the world’s only FDA, Health Canada and CE approved Total Artificial Heart: the SynCardia temporary Total Artificial Heart. There have been more than 850 implants of the Total Artificial Heart, accounting for more than 200 patient years of life on the device.

Originally used as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for people dying from end-stage biventricular failure. The Total Artificial Heart is the only device that provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.

For additional information, please visit: http://www.syncardia.com
or follow SynCardia on Twitter – @SynCardia_News



CONTACT:

SynCardia Systems, Inc.
Don Isaacs
Vice President of Communications
Cell: 520-955-0660

KEYWORDS:   United States  Europe  North America  Arizona  France

INDUSTRY KEYWORDS:   Surgery  Health  Cardiology  Hospitals  Medical Devices  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.